ArticleFuture science OA2025
Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recruitment of underrepresented racial and ethnic groups in clinical trials remains a challenge.
methodsThe ClinicalTrials.gov database was queried for phase III trials related to non-Hodgkin lymphoma (NHL), leukemia, and multiple myeloma (MM). A reference population was sourced from the Surveillance, Epidemiology, and End Results (SEER) database.
resultsA total of 53,821 pooled participants from 119 phase III trials were included in the analyses. Race and ethnicity data were reported in 95.8% and 81.5% of trials, respectively. Globally, the majority of participants were predominantly White (77.3%), followed by Asian (8.2%), Black/African American (5.4%), American Indian/Alaska Native (0.4%), and Native Hawaiian/Other Pacific Islander (0.2%), while Hispanic/Latino individuals constituted 11.0% of trial participants. In comparison to data in SEER, the proportions were lower for Asian/Pacific Islander and Hispanic/Latino across all cancers, and for Black/African American and American Indian/Alaska Native in leukemia and MM in US only trials.
conclusionsDespite progress, reporting and representation of non-White population remain insufficient in trials. Innovative strategies to enhance representation in trial enrollment are warranted, as well as the utilization of real-world data to establish recruitment goals by more effectively assessing the demographic and geographic distribution of target patient populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.